EE230 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in Canada
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.520
https://www.valueinhealthjournal.com/article/S1098-3015(25)00645-X/fulltext
Title :
EE230 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)00645-X&doi=10.1016/j.jval.2025.04.520
First page :
Section Title :
Open access? :
No
Section Order :
10024